Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Satellos Bioscience ( (TSE:MSCL) ) has provided an announcement.
Satellos Bioscience has called its annual general meeting of shareholders for June 17, 2026, to be held in a virtual-only format via live audio webcast, with shareholders of record as of May 12, 2026 eligible to participate. The meeting will address routine but important governance matters, including receipt of audited financial statements for the year ended December 31, 2025, election of the board of directors, and reappointment of PricewaterhouseCoopers LLP as auditors, underscoring the company’s ongoing compliance and engagement with its investor base.
Management has circulated a detailed information circular dated May 14, 2026, along with proxy and voting instruction forms, and is urging shareholders—particularly those holding shares through intermediaries—to vote in advance via proxy. The board, which unanimously supports the resolutions, is emphasizing proper registration and proxy procedures to ensure voting rights can be exercised in the fully virtual setting, a step aimed at maintaining orderly corporate governance and safeguarding shareholder participation despite the absence of an in-person meeting.
The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$23.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.
Spark’s Take on MSCL Stock
According to Spark, TipRanks’ AI Analyst, MSCL is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and continued cash burn), partially offset by a debt-free balance sheet. Technicals are mildly negative with limited momentum, and valuation metrics provide limited support due to negative earnings and no indicated dividend.
To see Spark’s full report on MSCL stock, click here.
More about Satellos Bioscience
Satellos Bioscience Inc. is a Canadian biotechnology company based in Toronto, focused on developing therapies in the life sciences sector. The company is listed as a foreign private issuer in the U.S. and files its reports under Form 40-F, reflecting its cross-border capital markets presence and responsibilities to international shareholders.
Average Trading Volume: 25,084
Technical Sentiment Signal: Sell
Current Market Cap: C$207.3M
See more data about MSCL stock on TipRanks’ Stock Analysis page.